Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

RPT-FEATURE-As smokers spark up e-cigs to quit, traditional aids suffer

Thu, 29th Jan 2015 06:00

(Repeats with no changes to text)

By Jilian Mincer

NEW YORK, Jan 29 (Reuters) - When Marty Weinstein decided toquit smoking, he took a friend's advice and tried electroniccigarettes rather than government-approved nicotine replacementproducts.

Weinstein, 58, has gone from a pack a day nine months ago tothe equivalent in nicotine of four or five cigarettes. Thee-cigs have a familiar look and feel, and quench his desire tohold on to a cigarette and puff.

"I fully understand I'm still addicted to nicotine," saidWeinstein, a Connecticut taxi driver who had smoked for morethan 20 years. "But I'm now so much healthier."

E-cigarettes, metal tubes that heat liquids typically lacedwith nicotine and deliver vapor when sucked, are transformingthe market for smoking cessation products and slowing the $2.4billion in global sales of long-standing aids such as nicotinepatches and gums. But their impact on health remains unclear,experts say, raising difficult questions for regulators who arestarting to impose limits on e-cigarette use.

E-cigarette makers in the United States are barred fromexplicitly marketing the products as smoking cessation devices,but have found ways to appeal legally to smokers who arethinking of quitting.

"You never say 'quit' because it's not approved by the FDAas a smoking cessation device," said Jose Castro, the chiefexecutive of A1 Vapors in Miami, referring to the U.S. Food andDrug Administration.

A1 Vapors runs an ad on its website urging customers to"kiss tobacco goodbye" and give themselves the "gift of yourlife. literally", adding a disclaimer that e-cigs are not asmoking cessation product.

E-cigarettes, or e-cigs, have only come into widespread usein the past few years, but have already made inroads intotraditional quitting therapies.

About a third of British smokers trying to quit were usinge-cigarettes, according to a University College London survey inJanuary of 1,800 people, including 450 smokers.

E-cigs are used by almost twice as many people asgovernment-approved nicotine gums, lozenges and patches,according to the survey. That was a reversal from 2011, whenonly about 5 percent of people were using e-cigarettes and morethan 30 percent used over-the-counter products.

Similar data is not yet publicly available for the UnitedStates.

Worldwide sales of all nicotine replacement therapies grewjust 1.2 percent last year, to almost $2.4 billion, according todata from commercial researcher Euromonitor. U.S. sales, at $900million, grew 0.2 percent, and are expected by Euromonitor todrop this year by that amount.

Big tobacco companies like Altria, Lorillard and Reynolds American have rushed into the e-cig market.The entire U.S. market for "vapor devices" such as e-cigs grewin 2014 by 40-50 percent to $2.5 billion to $3 billion,Euromonitor said. The global market is worth $5 billion.

RULES ON E-CIGS TIGHTENING

Mark Strobel, a consumer health analyst at Euromonitor, saide-cigarettes have slowed nicotine replacement therapy sales,along with relatively high prices and a shrinking population ofsmokers, especially in the United States.

"For some consumers it has been a direct substitution."

GlaxoSmithKline (GSK) and Johnson & Johnson don't break out the data on their smoking cessation products,which are relatively small parts of their sales, but thecompanies have noted the change.

"It's definitely taken a bit of our market, no question atall - but there's a lot of competition in that space," GSK chiefexecutive Andrew Witty told Reuters in an interview this month.

GSK's nicotine replacement therapies and smoking cessationproducts include the brands Nicorette, NicoDermCQ and themedicine Zyban.

There is little long-term safety data on e-cigarettes,although some healthcare professionals say they may be betterfor consumers than tobacco cigarettes because they have nocarbon monoxide and fewer cancer-causing chemicals.

A growing number of states, cities and countries - includingIsrael and Australia - are considering or have approvedlegislation to ban or limit the devices or the liquids, whichcome in exotic flavors from bacon to bubble gum.

California's top public health official on Wednesday slammede-cigs as addictive, saying they were leading to nicotinepoisoning among children and threatened to unravel the state'sdecades-long effort to reduce tobacco use.

Earlier this week, California introduced a bill that wouldban the devices in public places, and New York Gov. Andrew Cuomoproposed a similar ban earlier this month.

Last year, the World Health Organization recommended thatsmokers should be encouraged to try already approved treatmentsrather than e-cigarettes. The FDA last April proposed rules forelectronic cigarettes that would, among other things, ban salesto those under 18, but not restrict flavored products, onlinesales or advertising.

MAKING SMOKING COOL AGAIN?

Many health experts worry that e-cigarettes will becomeestablished as smoking cessation aids before enough research isdone to determine their health impact. Another concern is thatthey may stop people from quitting tobacco completely and deterpeople from trying potentially more effective methods.

Dr. Albert Rizzo, senior medical advisor for the AmericanLung Association, said that when patients ask about theproducts, he tells them it's good that they are trying to quitbut: "We don't know enough to recommend them."

Some healthcare professionals said that even if they are notopposed to e-cigarettes, they are concerned about theirmarketing, especially to young people.

The Federal Trade Commission declined to comment on specifice-cig ads but said "advertising must be truthful, non-deceptiveand supported by competent and reliable scientific evidence."

E-cigs risk bringing the "cool" back to smoking, reversingthe progress over decades in which smoking has become lesssocially acceptable, said Dr. Robert K. Jackler, a professor atStanford University School of Medicine.

"A lot of us are very concerned about the renormalizationphenomenon," he said. "These glamorize smoking behavior."

Still, some doctors point to the low efficacy of traditionalways to quit smoking.

"They have better results than placebos, but their rates ofsuccess are quite low," said Dr. Michael Siegel, a professor atthe Boston University School of Public Health, who saide-cigarettes are an alternative, especially for people who havetried the conventional therapies and failed. (Additional reporting by Kate C. Kelland and Ben Hirschler inLondon; editing by Peter Henderson and Stuart Grudgings)

More News
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.